Selective inhibition of IL-36 cytokines (also members of the IL-1 family) is being explored with several molecules including spesolimab, a mAb targeting IL-36 receptor, currently under investigation in clinical trials for moderate-to-severe HS. This evidence concerns the gene IL1B and histiocytic sarcoma.